Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) · Sponsor: Novartis Pharmaceuticals
The purpose of this open-label, single arm, multicenter, phase 3 study is to assess the pharmacokinetics of iptacopan in pediatric patients and to assess whether iptacopan is safe and well tolerated when used for the treatment of pediatric paroxysmal nocturnal hemoglobinuria (PNH) patients 2 to \< 18 years of age.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Childrens Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| St Jude Childrens Research Hospital | Memphis, Tennessee, United States | Recruiting |
| Novartis Investigative Site | Brasília, Federal District, Brazil | Recruiting |
| Novartis Investigative Site | Natal, Rio Grande do Norte, Brazil | Recruiting |
| Novartis Investigative Site | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| Novartis Investigative Site | Santo André, São Paulo, Brazil | Recruiting |
| Novartis Investigative Site | São Paulo, São Paulo, Brazil | Recruiting |
| Novartis Investigative Site | São Paulo, São Paulo, Brazil | Recruiting |
| Novartis Investigative Site | Cali, Valle del Cauca Department, Colombia | Recruiting |
| Novartis Investigative Site | Berlin, Germany | Recruiting |
| Novartis Investigative Site | Genova, GE, Italy | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06934967